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Backgound: The importance of airway inflammation has been highlighted in the pathophysi-
ology of asthma. Even in controlled asthmatics treated with inhaled corticosteroid (ICS),
residual airway inflammation is reported. Systemic therapy with oral leukotriene receptor
antagonist, pranlukast, may have additive effects to improve asthma control.
Methods: Twenty-five controlled asthmatics treated with ICS or ICS plus long-acting b2-agonist
(LABA) were enrolled for a randomized crossover trial evaluating the effect of additional oral
pranlukast. The patients were assigned to two groups receiving ICS (þLABA) or ICS
(þLABA) þ pranlukast for 8 weeks. After washout period, two groups were switched over for
another 8 weeks. Fraction of exhaled nitric oxide (FeNO), lung function tests, peak expiratory
flow (PEF) and asthma control test (ACT) were evaluated at the beginning and end of each
period. Central airway NO flux (J’awNO) and peripheral airway/alveolar NO concentration
(CANO) were measured and adjusted for axial NO back-diffusion.
Results: FEV1, % predicted, forced expired flow (FEF) 25e75, % predicted, morning PEF and ACT
were significantly increased after the addition of pranlukast. Oral pranlukast administration
significantly decreased both CANO and corrected CANO.roid; LABA, long-acting b2-agonist; NO, nitric oxide; FeNO, fraction of exhaled nitric oxide; J’awNO,
peripheral airway/alveolar nitric oxide concentration; LTRA, leukotriene receptor antagonist; COPD,
se; PEF, peak expiratory flow; ACT, asthma control test; SFC, salmeterol/fluticasone propionate
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Effect of pranlukast in stable asthma 509Conclusions: The addition of oral pranlukast to ICS or ICS þ LABA therapy may improve asthma
control with reducing distal airway inflammation.
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Asthma is an airway inflammatory disease of uncertain
etiology, involving the large and small airways and alveoli
resulting in varying airway hyper-responsiveness and bron-
choconstriction. Current guidelines for asthma manage-
ment concur that inhaled corticosteroids (ICS) are the
mainstay of anti-inflammatory therapy in asthma.1 Long-
acting b2-agonist (LABA) is recommended as add-on
therapy to ICS in patients with moderate persistent
asthma that is not well-controlled by regular ICS admin-
istration.Even though asthma symptoms are stable with ICS
or ICS plus LABA therapy, residual airway inflammation
often occurs in both central and peripheral airways in the
lung,2e5 which may lead to airway remodeling.
Recent studies have redirected attention to the role of
airway inflammation in both the central and the small
airways in asthma. Several studies using lung tissues from
asthmatic patients revealed inflammatory and structural
changes in the small airways and alveoli, which were
comparable to those within the central airways.6e8 More-
over, the severity of peripheral airway changes has been
correlated with disease instability, resistance to therapy
and excessive airway narrowing.9,10 Therefore, not only the
central airways but also the distal airways should be
important therapeutic targets in optimization of asthma
control and prevention of airway remodeling.11 However,
routine approaches, such as lung function tests, are limited
by their test-retest variability and lack of specificity in
reflecting small airways inflammation.
Measurement of the fraction of exhaled nitric oxide
(FeNO) is a relatively simple, non-invasive test for moni-
toring endogenous inflammatory signals and responses to
therapy in asthma. Tsoukias and George have developed
a two-compartment model that has been used to quantify
the amounts of FeNO arising from the large central airways
and the peripheral small airway/alveolar site separately.12
Several studies have shown increased levels of both central
airway NO flux (J’awNO; nl/s) and peripheral airway/alveolar
NO concentration (CANO; ppb) in asthma. In particularly,
CANO is correlated with eosinophil cationic protein levels
and eosinophil count in bronchoalveolar lavage fluid.13e15
CANO is a reproducible parameter reflecting peripheral
airway inflammation, which does not vary diurnally and can
be measured in asthmatic by simple breathing maneuvers.
It has been reported that elevated FeNO at 50 ml/s in
asthmatics was reduced by ICS therapy,16,17 whereas
systemic therapy, such as oral corticosteroid administra-
tion, was needed to reduce increased CANO.
15,18
Leukotriene receptor antagonists (LTRAs) are recom-
mend as an optimal alternative for add-on therapy to ICS or
ICS plus LABA in guidelines.1 Pranlukast, a systemic deliv-
ered LTRA, has been shown to have clinical efficacy inmoderate to severe asthma when added to ICS therapy.19
While the improvements in FEV1 are generally modest,
asthma symptoms and quality of life appear to be improved
to greater degree with LTRA administration than FEV1,
20
which could be due to systemic therapeutic effects with
better adherence for LTRA as an orally administered agent.
However, the therapeutic benefit of add-on LTRA to
controlled asthma has not been fully established.The aim of
this prospective crossover study was to investigate the
impact of add-on pranlukast administration to stable asth-
matics treated with ICS alone or ICS plus LABA therapy. In
particular, we evaluated both large and small airway/
alveolar sites in terms of inflammation using NO
measurement.
Materials and methods
Study subjects
We recruited patients with asthma whose disease was
classified as “controlled” according to the GINA criteria of
asthma control.1 Briefly, the patients were free from
asthma symptoms, limitations of activities, exacerbation
and more than three rescue treatments a week even when
required. Each patient had received ICS or ICS plus LABA for
1 year or more, with no change in dose within the previous 8
weeks.Patients who met the following criteria were
excluded from this study: 1) treatment with LTRA in the
previous 3 months, 2) treatment with oral or intravenous
corticosteroids in the previous 4 weeks, 3) chronic
obstructive pulmonary disease (COPD) using high-resolution
computed tomography or lung function tests, and exhibited
no or weak responsiveness against an inhaled short-acting
bronchodilator.
Ethics and study design
This randomized crossover trial was conducted at Hama-
matsu University School of Medicine. Our Institutional
Review Board approved the study protocol and each patient
gave written informed consent. The study was registered in
the UMIN Clinical Trials Registry (UMIN-CTR) system (http://
www.umin.ac.jp/. NO. UMIN 000003781).
The patients were randomly divided into two groups
receiving add-on oral pranlukast (450 mg daily) and no-add-
on treatment for 8 weeks (phase 1).After a washout period
(4e8 weeks), the two groups were switched over to the
opposite group for 8 weeks (phase 2) so that the trial was
performed in a crossover manner (Fig. 1).FeNO at 50, 100,
150, and 200 ml/s, lung function tests, peak expiratory flow
(PEF) in the morning and evening, and asthma control test
(ACT) were evaluated at the beginning and the end of each
phase 1
8 weeks
phase 2
8 weeks
wash out
4-8 weeks
Add-on pranlukast
Add-on pranlukastNo-add-on pranlukast
No-add-on pranlukast
ICS or 
ICS plus LABA
Randomized
Distribution
Measurement of
lung function tests,
FeNO and ACT
n = 25
n = 13
n = 12
Figure 1 Study design. The patients were randomly divided into two groups receiving add-on oral pranlukast (450 mg daily) and
no-add-on treatment for 8 weeks (phase 1).After a washout period (4e8 weeks), the two groups were switched over to the opposite
group for 8 weeks (phase 2) so that the trial was performed in a crossover manner. Measurement of lung function tests, FeNO and
ACT, were performed at the beginning and end of phase 1 and 2. FeNO, fraction expiratory nitric oxide; ACT, asthma control test;
ICS, inhaled corticosteroid; LABA, long-acting b2-agonist.
510 H. Yasui et al.period. J’awNO and CANO were calculated using the two-
compartment model12 and corrected by axial NO back-
diffusion.21 If the patients had already used therapeutic
drugs other than LTRA, they were allowed to use these
medications with no change in the dosage or regimen.
Patients who had asthma exacerbation that required
hospitalization were removed from the study. Rescue
inhalation of a short-acting b2-agonist was used on demand
to control symptoms throughout the study.
Measurement of FeNO
All subjects abstained from food and coffee for 2 h and
alcohol for 12 h prior to the studies. FeNO was measured
prior to spirometry at 4 separate constant expiratory flow
rates: 50, 100, 150 and 200 ml/s, in triplicate and the mean
of 3 values obtained within 10% of each other was reported
as determined using a Sievers NOA280i chemiluminescence
analyzer (GE Analytical Instruments, Boulder, Colorado,
USA). We used a restricted exhaled breath technique to
exclude nasal NO. While sitting, subjects inhaled NO-free
air to their total lung capacity and then exhaled into the
analyzer mouthpiece attached to a one-way valve. Any
exhalation that did not meet the American Thoracic
Society requirements was not accepted by the REB system
(GE Infrastructure Water & Process Technologies). The
technique of Tsoukias and George was used to caluculate
J’awNO (y intercept) and CANO (slope) using a linear
regression line with data from at least 3 separate expira-
tory flow rates required for each subject.12 Correction was
made for potential underestimation of J’awNO due to axial
back-diffusion of NO using the method of Condorelli
et al.21 by multiplying J’awNO by a factor of 1.7. Further-
more, to adjust for possible spurious overestimation of
values for CANO, initial uncorrected J’awNO was divided by
a correction factor of 0.53 and subtracted from initial
uncorrected CANO.Statistical analysis
The efficacy of pranlukast administration was assessed by
comparing the changes in lung function tests, morning and
evening PEF, asthma symptoms and FeNO levels. All values
were analyzed using StatView version 5 (SAS Institute Inc.
North Carolina, USA). Data for those with asthma were
initially analysed to determine normality of distribution
using KolmogoroveSmirnov test. Normally distributed vari-
ables are described as means and standarad deviations,
while non-normally distributed variables (FeNO data) were
expressed as medians with interquartile ranges (medians,
interquartile ranges). The comparison of lung function
tests, PEF and ACT, was carried out using Student’s t-test
for paired samples. The Wilcoxon matched-pair signed-rank
test was used for FeNO. Values of p < 0.05 were considered
significant.Results
Characteristics of the patients
A total of 25 patients were enrolled in this study.All
subjects completed both add-on oral pranlukast treatment
and no-add-on treatment and were included in the analyses
without any adverse effects. The characteristics of the
patients at enrollment are shown in Table 1. Briefly, the
median age was 66 years, 16 patients were women (64%)
and the median duration of asthma was 132 months.
Seventeen patients (68%) were atopic as judged by clinical
manifestation and their serum IgE level. Among the group,
17 patients had never smoked and 8 patients were former
smokers. All subjects used ICS or ICS plus LABA, and the
median dose of ICS was 400 mg (fluticasone propionate
conversion).
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There were no significant differences in the lung function
tests, morning PEF and ACT at the beginning of each period.
During the no-add-on treatment period, no significant
changes were found in lung function tests, PEF and ACT
between the beginning and the end of the period (Table 2).
FEV1, % predicted, forced expired flow (FEF) 25e75, % pre-
dicted, morning PEF and ACTwere significantly increased at
the end of add-on oral pranlukast period compared with
those at the beginning of the period.
NO Gas exchange
The values of FeNO at 50 ml/s at the beginning of add-on
oral pranlukast treatment period and no-add-on treatment
period were almost identical. No significant change was
found in the FeNO at 50 ml/s between the beginning and
the end of each period (Fig. 2A). The value of J’awNO was
equal between the beginning and the end of the add-on oral
pranlukast treatment period (1.35, 0.55e2.15 and 1.10,
0.40e2.50 nl/s, respectively, p Z 0.44) as well as no-add-
on treatment period (1.50, 0.80e3.30 and 1.50,
0.50e2.70 nl/s, respectively, p Z 0.70) (Fig. 2B). Inter-
estingly, there was a statistically significant reduction in
CANO level at the end of the oral pranlukast treatment
period (4.10, 2.30e6.60 ppb) compared with that at the
beginning (6.45, 4.23e10.70 ppb) (p Z 0.04) (Fig. 2C). As
shown in Fig. 3, the results of J’awNO and CANO after
correction for NO axial back-diffusion indicated a similar
tendency, and corrected CANO was significantly lower at the
end of oral pranlukast treatment period compared with
that at the beginning of the period (p Z 0.04).
Discussion
In the present study, we have shown that additional
administration of oral pranlukast, a leukotriene receptor
antagonist, to stable asthmatic patients under ICS or ICS
plus LABA therapy have clinical benefit to improve asthmaTable 1 Patient characteristics.
Number of patients 25
Female sex, n (%) 16 (64)
Age (year) 66 (24e86)a
Duration of asthma (month) 132 (6e750)a
No. with atopy (%) 17 (68)
No. of former smokers (%) 8 (32)
Inhaled corticosteroid
dose (mg)b
400 (200e800)a
No. with treatment
ICS only 9
SFC 10
ICS plus LABA 6
ICS, inhaled corticosteroid; SFC, salmeterol/fluticasone propi-
onate combination; LABA, long-acting b2-agonist.
a Data are expressed as median (range).
b Fluticasone equivalent.symptoms and physiology of the lung, FEV1, % predicted,
FEF25e75, % predicted and morning PEF.In addition, add-on
oral pranlukast significantly reduced the CANO level,
a parameter of small airway inflammation, without any
changes of FeNO at 50 ml/s and J’awNO. These results
indicate that add-on oral administration of pranlukast has
additive therapeutic benefit in asthma under ICS or ICS plus
LABA therapy together with decreasing small airway
inflammation.
Several clinical studies have already shown the thera-
peutic effects of pranlukast in asthma.19,22 Previous reports
have demonstrated that pranlukast had steroid-sparing
effects when it was administered to moderate to severe
asthmatics combined with ICS.19,22 However, it has
remained to be determined whether add-on oral pranlukast
for controlled asthmatics treated with ICS or ICS plus LABA
has additional benefit. In the present study, we have shown
that add-on pranlukast administration has additive thera-
peutic effects, such as increasing ACT, FEV1, % predicted,
FEF25e75, % predicted and morning PEF, even in controlled
asthmatics under ICS or ICS plus LABA therapy. Recently,
Ohbayashi et al. reported that add-on pranlukast with sal-
meterol/fluticasone propionate combination (SFC) did not
change any pulmonary function index in well-controlled
moderate asthma.5 All the patients in their study were
treated with ICS plus LABA as SFC, whereas 9 of 25 patients
in the present study were treated with ICS only (without
LABA), which may have caused different effects of pran-
lukast administration in each study, especially in terms of
bronchodilation. Further investigation will be needed to
determine the different effects of add-on pranlukast to the
patients treated with ICS only and ICS plus LABA.
The importance of distal airway inflammation has been
highlighted in the pathophysiology of asthma. Increased
mucous plugging and thickening of the smooth muscle,
submucosa and adventitia in the peripheral airways have
been demonstrated in the lung of patients with asthma.23
Activated eosinophils and expression of interleukin-5
mRNA were also increased in the distal lung of patients
with mild-to-moderate asthma.24,25 In a clinical context,
small airway inflammation is associated with increased risk
of future exacerbation and increased bronchial hyper-
responsiveness, which cause severe asthma,26 however,
ICS is not sufficient to reduce CANO in asthmatics.
14
Previous studies demonstrated that a major site of
inflammation in distal airway is outer wall,11,27 which
indicated that inhaled therapy may be insufficient to
control distal airway inflammation and systemic therapy
may be more preferable. The effects of oral LTRA admin-
istration to reduce peripheral airway inflammation in
asthma have been reported.5,28 Zeidler et al. have found
that montelukast, another LTRA, resulted in significantly
less regional air-trapping on high-resolution computed
tomography images and improvement in quality of life
scores.28 In the present study, add-on oral pranlukast
administration to ICS or ICS plus LABA resulted in signifi-
cant reduction of CANO without any changes of FeNO at
50 ml/s and J’awNO, and improved asthma control. The
action of pranlukast in the peripheral airway might lead to
the improvement of asthma control.
In this study, we used a two-compartment model of NO
exchange dynamics to assess central and distal airway
Table 2 Results of lung function and asthma control test (ACT).
Add-on pranlukast No add-on pranlukast
Beginning End P value Beginning End P value
FVC (L) 2.68  0.97 2.70  0.95 0.16 2.70  1.03 2.70  0.99 0.63
FVC, % predicted (%) 94.1  24.6 95.3  23.0 0.30 93.0  24.4 93.6  26.5 0.86
FEV1 (L) 1.93  0.91 2.00  0.91 0.05 1.91  0.92 1.90  0.92 0.80
FEV1, % predicted (%) 80.8  26.1 84.0  25.3 0.03 79.5  25.9 80.7  27.8 0.80
FEV1/FVC (%) 70.0  13.1 71.4  11.2 0.28 68.8  10.8 69.9  12.6 0.40
FEF25e75, % predicted (%) 48.4  35.3 53.4  33.9 0.04 43.8  27.0 49.4  35.4 0.40
FEF50, % predicted (%) 55.6  35.3 57.3  33.5 0.77 51.0  27.5 56.5  35.0 0.43
FEF75, % predicted (%) 45.0  32.9 46.6  29.2 0.67 45.2  30.1 46.6  31.2 0.78
morning PEF (L/min) 326.4  116.4 345.0  118.0 0.01 327.9  112.5 324.2  133.2 0.85
ACT 21.4  2.9 22.4  2.6 0.02 22.1  3.0 21.2  3.1 0.09
FEF, forced expired flow; PEF, peak expiratory flow; ACT, asthma control test. Data are expressed as mean  SD.
512 H. Yasui et al.inflammation separately.12 Recent studies have also
demonstrated, both experimentally and theoretically,
axial back-diffusion of NO from proximal to peripheral
airway/alveoli against the direction of exhalation,21 which
causes underestimation of J’awNO and overestimation of
CANO levels. In the present study, we evaluated J’awNO and
CANO using correction for NO axial back-diffusion according
to the previous reports.21 The present data demonstrated
that both CANO level and corrected CANO for axial back-
diffusion were significantly decreased by add-onFigure 2 Results of FeNO at 50 ml/s, J’awNO and CANO at the begin
pranlukast period. The value of FeNO at 50 ml/s and J’awNO were n
each period (A, B). Add-on pranlukast administration significantly
J’awNO, central airway nitric oxide flux; CANO, peripheral airway/alve
and interquartile ranges. The median is represented as a horizontapranlukast to ICS or ICS plus LABA (Figs. 2C and 3B), which
constitutes an advantage for the treatment of distal airway
inflammation.
Some previous studies described that no significant
change of CANO was found after the addition of oral LTRA
treatment to ICS therapy in asthmatics.16,29,30 In each
study, the researchers used various kinds of LTRA (e.g.,
montelukast,29 zileuton30) which may be one of the reasons
for the difference in results. The differences of background
in the subjects and study design also may cause differentning and end of the add-on pranlukast period and the no-add-on
ot significantly different between the beginning and the end of
reduced CANO level (C). FeNO, fraction of exhaled nitric oxide;
olar nitric oxide concentration Figures data include the median
l bar.
Figure 3 Results of J’awNO and CANO using correction for NO axial back-diffusion. Corrected J’awNO values were not significantly
different between the beginning and the end of each period (A). Add-on pranlukast administration significantly reduced corrected
CANO level (B). Figures data include the median and interquartile ranges. The median is represented as a horizontal bar.
Effect of pranlukast in stable asthma 513results in each study. In the present study, the subjects
were controlled asthmatics under the treatment of ICS or
ICS plus LABA according to the guideline. Add-on pranlu-
kast period was 8 weeks in this study, which was longer
than the other reports. Although the reduction of CANO was
modest and not statistically significant, Fritscher and
coworker reported that the addition of oral montelukast to
inhaled fluticasone might decrease small airway inflam-
mation in mild asthma.16 Some limitations to these studies
including ours should be noted. They were opened-label,
non-controlled pilot studies on a relatively small number
of patients. This study is important in terms of being the
first randomized crossover trial observing the change of
CANO after additional oral LTRA treatment in stable asth-
matics, which is an advantage of the present study over the
others.
In summary, the present study has demonstrated that
add-on pranlukast treatment to ICS or ICS plus LABA
improved asthma control together with a significant
reduction of CANO. Although asthmatic patients treated
with ICS or ICS plus LABA are clinically stable, there is
a possibility that small airway inflammation is not regulated
completely and add-on oral pranlukast decreases residual
small airway inflammation, which can improve asthma
control. A long-term study involving assessment of various
airway inflammation markers and pulmonary functions is
required to confirm the benefit of add-on pranlukast
administration in stable asthma.
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